Liqin Zheng

Liqin Zheng

Auto-generated profile, based on publicly available information

Liqin Zheng

Department of Hand Surgery and Wound Repair, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2023 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
XHXiuhong Huang
Xiuhong Huang
LZLiqin Zheng
Liqin Zheng
YZYueshan Zhou
Yueshan Zhou
SHShaonan Hu
Shaonan Hu
WNWancheng Ning
Wancheng Ning
SHShaohong Huang
Shaohong Huang

14 August 2025 in Materials Today Bio
Verified
Journal Article
Open access
XHXiuhong Huang
Xiuhong Huang
ZLZiling Lin
Ziling Lin
MRMingshu Ruan
Mingshu Ruan
PHPeizhen Huang
Peizhen Huang
HDHongmei Ding
Hongmei Ding
LZLiqin Zheng
Liqin Zheng
Diabetic wound (DW) complications, driven by persistent oxidative stress, unresolved inflammation, and vascular dysfunction, present a critical clinical challenge. Given mitochondria's pivotal role in inflammatory regulation, intercellular mitochondrial transfer emerges as a promising therapeutic target for DW management. In this study, we engineered a ROS/glucose/pH-triple responsive nanoplatform (WOC) via coordination-driven assembly of tungstate anions (WO4 2-) and chitosan oligosaccharide (COS) to synchronize immunomodulation and angiogenesis for adaptive DW regeneration. The WOC platform demonstrated glucose/pH-triggered release of bioactive components with moderate ROS scavenging capacity, enabling real-time monitoring via visible colorimetric transition. By enhancing mitochondrial bioenergetics, WOC polarized macrophages to M2 phenotype and orchestrated vesicles-dependent mitochondrial transfer to injured endothelial cells, restoring vascular function through upregulated angiogenesis genes, enhanced migration, and tube formation. In diabetic rat models, WOC accelerated wound closure evidently, resolving inflammation and promoting scarless regeneration via balanced collagen deposition. This work establishes mitochondrial transfer as a promising strategy, offering a tunable nanotherapeutic approach to recalibrate cellular cross-talk and microenvironment dynamics in DW healing.

11 February 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XHXiuHong Huang
XiuHong Huang
CLChiHung Li
ChiHung Li
YLYiuMan Lau
YiuMan Lau
ZLZiLing Lin
ZiLing Lin
COChongZhi OuYang
ChongZhi OuYang
LZLiQin Zheng
LiQin Zheng
Total flavonoids of Rhizoma drynariae (TFRD) possess the ability to enhance bone formation by promoting the coupling of angiogenesis and osteogenesis. However, the limited duration of serum concentration necessitates frequent oral administration. Designing TFRD as a sustained-release agent could enhance patient’s compliance and extend efficacy. Mesoporous silica nanoparticles (MSNPs) were used as a carrier for the preparation of a sustained-release agent containing TFRD (TFRD@MSNPs). Material characterization confirmed the successful loading of TFRD onto MSNPs. Subsequently, HUVECs were treated with varying concentrations of TFRD or TFRD@MSNPs to evaluate their effects on proliferation and migration ability. The secretion levels of VEGF, VCAM-1, EGF, TGF-β1, and type H endothelial markers (CD31 and EMCN) were assessed. BMSCs were cultured in conditioned medium derived from HUVECs induced by either TFRD or TFRD@MSNPs to evaluate their osteogenic potential in vitro. Gene expressions of ALP, OCN, and RUNX2, alkaline phosphatase activity, and calcium deposition were measured. The mass fraction of TFRD in the sustained release system TFRD@MSNP was approximately 60%. An appropriate concentration (< 400 µg/mL) of TFRD promoted the proliferation and migration of HUVECs, inhibited the secretion of TGF-β1, and increased the expression levels of VEGF, VCAM-1, EGF, CD31, and EMCN. The conditioned medium from HUVECs induced by TFRD significantly enhanced the osteogenic differentiation potential of BMSCs. An appropriate concentration of TFRD@MSNPs promoted the proliferation and migration of HUVECs, as well as the expression levels of CD31 and EMCN, but had no significant effect on VEGF, VCAM-1, EGF, or TGF-β1 secretion. The conditioned medium from HUVECs induced by TFRD@MSNPs increased ALP, OCN, and RUNX2 gene expression in BMSCs to varying degrees. Compared to the conditioned medium induced by TFRD in HUVECs, the conditioned medium induced by TFRD@MSNPs resulted in more calcium deposits in BMSCs. The sustained-release agent TFRD prepared by MSNPs can effectively promote the osteogenic differentiation of BMSCs through the coupling effect of angiogenesis and osteogenesis in vitro. These findings suggest that using MSNPs to formulate TFRD as sustained-release agent holds potential for clinical application, but the specific mechanism remains to be elucidated.